Remikiren

{{short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 464380766

| IUPAC_name = (2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-4-yl)propanamide

| image = Remikiren.svg

| tradename =

| pregnancy_AU =

| pregnancy_US =

| legal_AU =

| legal_UK =

| legal_US =

| legal_status = Investigational

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 126222-34-2

| ATC_prefix = C09

| ATC_suffix = XA01

| PubChem = 6324659

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00212

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 4884377

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = LC7FBL96A4

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D09038

| ChEBI = 8803

| ChEMBL_Ref = {{ebicite|correct|EBI}}

| ChEMBL = 31601

| C=33 | H=50 | N=4 | O=6 | S=1

| smiles = O=S(=O)(C(C)(C)C)C[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C2CC2)Cc3cnc[nH]3)Cc4ccccc4

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = UXIGZRQVLGFTOU-VQXQMPIVSA-N

}}

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.{{cite journal |vauthors=Richter WF, Whitby BR, Chou RC |title=Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals |journal=Xenobiotica |volume=26 |issue=3 |pages=243–54 |year=1996 |pmid=8730917 |doi=10.3109/00498259609046705}}